Decentralised Clinical Trials Market
Virtual Trials and Patient Centric Research
Traditional clinical trials require patients to travel frequently to large academic medical centres, a burden that limits participation and slows down drug development. Decentralised Clinical Trials (DCTs) leverage digital tools to bring the trial to the patient’s home. This involves telemedicine visits with investigators, wearable sensors to collect real world data, electronic consent (eConsent), and direct to patient shipment of investigational drugs. DCTs significantly improve patient recruitment and retention, especially for rare diseases and diverse populations, while also generating richer, more continuous data.
What Numbro covers:
Global adoption rate analysis of DCT elements (eConsent, Telemedicine Visits, Home Health Visits) by trial phase and therapeutic area. Technology vendor landscape mapping for eCOA (electronic Clinical Outcome Assessment) and connected device integration platforms. Regulatory guidance analysis from US FDA and EMA on DCT implementation and data integrity. Cost benefit analysis of hybrid trials (partly onsite, partly remote) versus fully decentralised models.
- Pharma clinical operations heads
- Clinical Research Organisation (CRO) project managers
- Digital health technology vendors
- Patient advocacy groups
